ibusinesslines.com March 23, 2018

Synergy Pharmaceuticals Inc 174% Potential Upside Now Implied by Rodman & Renshaw

25 January 2017, 08:48 | Kelvin Horton

Synergy Pharmaceuticals Inc 174% Potential Upside Now Implied by Rodman & Renshaw

Synergy Pharmaceuticals Inc 174% Potential Upside Now Implied by Rodman & Renshaw

According to consensus agreement of 6 analysts Synergy Pharmaceuticals Inc (NASDAQ: SGYP) will report earnings per share of $-0.2 in their quarterly report and it is expected to announce the company's results on 2/23/17. BlackRock Fund Advisors now owns 8,824,549 shares of the biopharmaceutical company's stock valued at $33,533,000 after buying an additional 3,120,748 shares during the last quarter.

If we look at the Volatility of the company, Week Volatility is 6.69%, whereas Month Volatility is at 6.15%. Currently, 15.3% of the shares of the company are sold short.

Executives hold 0.39 percent of the stock. Victory Capital, an Ohio-based fund reported 3,651 shares.

Biogen Inc. (NASDAQ: BIIB) [Trend Analysis] retains strong position in active trade, as shares scoring 0.11% to $280.66 in active trade session, while looking at the shares volume, around 1.97 Million shares have changed hands in this session. D E Shaw And Company holds 0% or 188,211 shares in its portfolio. Canaccord Genuity restated a "buy" rating and issued a $13.00 price objective on shares of Synergy Pharmaceuticals in a research report on Friday, October 21st. Dividends are mostly given in terms of cash payments, property or as shares of stock. The company has 0.80% insider ownership. Blackrock Japan Communication Ltd accumulated 644 shares or 0% of the stock.

05/12/2015 - Synergy Pharmaceuticals, Inc. was upgraded to " by analysts at Zacks.

Insider Transactions: Since September 16, 2016, the stock had 0 insider buys, and 4 sales for $20.41 million net activity. BRANCACCIO JOHN P had sold 2,518 shares worth $14,504 on Monday, September 19.

10/24/2016 - Synergy Pharmaceuticals, Inc. had its " rating reiterated by analysts at H.C. Wainwright. After $-0.22 actual EPS reported by Synergy Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -22.73% EPS growth.

Synergy Pharmaceuticals, Inc. (NASDAQ: SGYP) has its dividend (annual) of 0 while its Dividend Yield (annual) is 0%.

Trulance met the main goals of two late-stage studies in December on irritable bowel syndrome patients with constipation (IBS-C). "Synergy Pharmaceuticals, Inc.is headquartered in New York, New York". Large ranges indicate high volatility and small ranges indicate low volatility. Current price places the company's stock 28.95% away from its 200-day simple moving average, 5.13%, away from the 50-day average and also -4.19% away from 20-day average. Swiss National Bank increased its stake in shares of Synergy Pharmaceuticals by 67.8% in the third quarter. Rodman & Renshaw maintained Synergy Pharmaceuticals Inc (NASDAQ: SGYP) rating on Friday, December 23. It has been assigned a low target price of $6.5 and a high target price of $18. The firm has " rating given on Thursday, October 29 by Roth Capital. (NASDAQ: SGYP) now has a Mean Price Target of $11.5. Higgins has a 32.4% average return when recommending SGYP, and is ranked #4247 out of 4361 analysts.

SGYP has been the subject of several recent research reports. (NASDAQ: SGYP) was down -7.80% during the last trading session, with a day high of 6.71. Analysts mean target price for Twilio Inc. The firm earned "Outperform" rating on Thursday, January 5 by Oppenheimer.

In Synergy Pharmaceuticals Inc. TRULANCE is the first drug created to replicate the function of uroguanylin, a naturally occurring and endogenous human gastrointestinal (GI) peptide that is thought to stimulate fluid secretion which results in a stool consistency associated with more regular bowel function.

Other News

Trending Now

700 Employees Reportedly Getting Axed Next Week — Microsoft Layoffs
Business Insider notes that things are now tense at Microsoft, as employees keep hearing rumors of hundreds of jobs being cut. This is still not a huge number when compared to Microsoft's total workforce of approximately 113,000 people.

Dont Miss